PDLI Phase III Zamyl AML data

Protein Design (PDLI) said that in a Phase III study of 191 patients with acute myeloid leukemia (AML), the combination of its Zamyl humanized antibody with chemotherapy did not show a significant difference compared to chemotherapy alone on the primary endpoint of complete response rate within 70 days of starting treatment. The Zamyl group had an overall response rate of 43% compared to 26% for chemotherapy alone (p=0.015). PDLI expects to submit a BLA for Zamyl in the second half of 2003. ...